BridgeBio Oncology Therapeutics, Inc., or BBOT, said it granted two employees hired in July 2026 non-qualified stock options covering a combined 65,350 shares of common stock under its 2025 Inducement Plan. The awards were issued on August 10, 2026, with an exercise price of $9.28 per share, matching the Nasdaq closing price on the grant date. Vesting is set at 25% on the first anniversary of each employee’s applicable start date, with the remainder vesting in 36 equal monthly installments after that, subject to continued service. BBOT said the awards were made outside its stockholder-approved equity incentive plans and were approved by the compensation committee of its board of directors, which is comprised solely of independent directors, as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4) (an exchange rule covering hiring-related equity awards).